Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 70/100

Insmed To Present at the BofA Securities Health Care Conference 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Key Takeaway: Insmed Incorporated (Nasdaq: INSM) announced that its management team will participate in a fireside chat at the BofA Securities Health Care Conference 2024 on May 14, 2024. The event will take place in Las Vegas, NV, and will be accessible via live webcast. Insmed is known for its mission to improve the lives of patients with serious and rare diseases and is progressing a strong pipeline of investigational therapies. The company's commitment to innovative treatment options is underscored by its ongoing research efforts in various advanced technologies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is presenting at a significant healthcare conference, indicating visibility and engagement with investors.
  • The company focuses on transforming lives of patients with serious and rare diseases, highlighting a strong mission.
  • Insmed has a robust pipeline of investigational therapies, which reflects potential for future growth.

Full Press Release Details

BRIDGEWATER, N.J. , May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the BofA Securities Health Care Conference 2024 in Las Vegas, NV , on Tuesday, May 14, 2024 at 2:20 p.m. PT ( 5:20 p.m. ET ).
The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . The webcast will be archived for a period of 30 days following the conclusion of the live event.
About Insmed Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater , New Jersey , with additional offices and research locations throughout the United States , Europe , and Japan . Visit www.insmed.com to learn more.
Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 [email protected]
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

What is Insmed Incorporated's mission?

Insmed aims to transform the lives of patients with serious and rare diseases.

When is the BofA Securities Health Care Conference presentation?

The presentation is on May 14, 2024, at 2:20 p.m. PT.

Where can I access the live webcast of the event?

The webcast can be accessed on Insmed's investor relations website.

What is Insmed's first commercial product?

It is a first-in-disease therapy for a chronic, debilitating lung disease.

What types of therapies is Insmed developing?

Insmed is developing therapies for neutrophil-mediated diseases and rare pulmonary disorders.

Last updated: May 7, 2024